Spanish Pharma Stock News

The European stock market has recently experienced a downturn, with the pan-European STOXX Europe 600 Index falling by 2.21% amid concerns over inflated AI stock valuations and receding expectations for a U.S. interest rate cut. Despite these challenges, business activity in the eurozone continues to expand steadily, presenting potential opportunities for investors seeking stocks that may be undervalued relative to their intrinsic value. In this context, identifying stocks that are trading...

Amid renewed concerns over inflated AI stock valuations and receding expectations for a U.S. interest rate cut, European markets have seen a downturn, with major indices like the STOXX Europe 600 Index ending lower. In such an environment, identifying stocks that may be trading below their estimated value can offer potential opportunities for investors looking to navigate these challenging market conditions effectively.

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

Did you know there are some financial metrics that can provide clues of a potential multi-bagger? In a perfect world...

eDreams ODIGEO (BME:EDR) lowered its earnings guidance for 2026 and 2027, citing slower growth in its prime membership base and the effects of a shift toward flexible payment plans for subscribers. See our latest analysis for eDreams ODIGEO. eDreams ODIGEO’s share price has tumbled sharply, down 52% for the month and 59% year-to-date, reflecting fading momentum as investors digest the company’s lower earnings outlook and shifting growth profile. Despite a spike in recent net profit, the...

ACS, Actividades de Construcción y Servicios, S.A.'s ( BME:ACS ) healthy profit numbers didn't contain any surprises...

There's been a major selloff in eDreams ODIGEO S.A. ( BME:EDR ) shares in the week since it released its quarterly...

Enagás, S.A.'s ( BME:ENG ) investors are due to receive a payment of €0.324 per share on 23rd of December. This means...

Grifols (BME:GRF) shares have moved recently, capturing attention after an extended stretch of volatility. Investors are weighing near-term developments as they consider a changing backdrop for the pharmaceutical sector in Europe. See our latest analysis for Grifols. After a turbulent year marked by sharp swings, Grifols’ 8.2% share price return since January stands out, especially as this rise has come despite recent negative momentum, including a 17.3% drop over the last three months and...

eDreams ODIGEO S.A. ( BME:EDR ) shareholders that were waiting for something to happen have been dealt a blow with a...

Shareholders of Solaria Energía y Medio Ambiente, S.A. ( BME:SLR ) will be pleased this week, given that the stock...

ACS, Actividades de Construcción y Servicios, S.A. ( BME:ACS ) last week reported its latest third-quarter results...

Solaria Energía y Medio Ambiente has released its earnings results for the nine months ended September 30, 2025, reporting €258.91 million in revenue and €141.67 million in net income, both sharply higher compared to the previous year. Despite a slight decline in sales, the company achieved a very large year-on-year increase in net income, highlighting a marked improvement in profitability. We'll examine how Solaria's surge in net income, amid higher revenue, affects the company's investment...

Fomento de Construcciones y Contratas, S.A.'s ( BME:FCC ) price-to-earnings (or "P/E") ratio of 27.5x might make it...

If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. But...

Naturgy Energy Group, S.A.'s ( BME:NTGY ) price-to-earnings (or "P/E") ratio of 13.3x might make it look like a buy...

When companies post strong earnings, the stock generally performs well, just like Almirall, S.A.'s ( BME:ALM ) stock...

It looks like Viscofan, S.A. ( BME:VIS ) is about to go ex-dividend in the next three days. The ex-dividend date...

Key Insights Acciona's significant private companies ownership suggests that the key decisions are influenced by...

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Banco de Sabadell (BME:SAB) found itself in the spotlight after its Q3 2025 earnings reaffirmed full-year guidance and medium-term targets. However, investor focus quickly shifted following a prominent analyst downgrade citing geographic risks. See our latest analysis for Banco de Sabadell. Despite the recent analyst downgrade, Banco de Sabadell’s share price has soared over 71% year-to-date, reinforcing the market’s recognition of its turnaround and strong execution. Its one-year total...

Cellnex Telecom (BME:CLNX) just released its latest quarterly results, showing sales gains in both the third quarter and the nine-month period, but also a sharp rise in net losses compared to last year. See our latest analysis for Cellnex Telecom. The share price has been under pressure lately, with a 30-day return of -8.6% and a year-to-date decline of -16.4%, reflecting investor caution after Cellnex Telecom’s growing losses. Over the longer run, the 1-year total shareholder return stands...

Mapfre (BME:MAP) just released financial results for the nine months ended September 2025, posting net income of €829 million, up from €653.5 million a year earlier. This has drawn attention from investors. See our latest analysis for Mapfre. Mapfre shares have shown impressive momentum, with a 63.4% year-to-date share price return as investors react positively to stronger earnings and a revived growth narrative. The longer-term picture is just as compelling, as evidenced by a five-year total...

Banco Sabadell reported its Q3 2025 results, highlighting a recurrent return on tangible equity of 14.1%, confirmed guidance across all profit and loss lines, announced a second interim dividend payable in December, and outlined plans for an extraordinary dividend from the TSB divestment. An analyst downgrade followed, citing concerns about Sabadell’s growing reliance on the Spanish market after the TSB sale and questioning future revenue diversification. We'll examine how Sabadell's...